Common TitleCALIBRATE
Official Title A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
Phase Phase II
ClinicalTrials.gov NCT04143594
Treatments
Lenacapavir
Lenacapavir
Tradename:SunlencaClass:Capsid InhibitorsCategories Treatment-NaiveDual Therapy
Funding
IndustryGilead Sciences
References
- Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023;10:e15-e23.